Sep 11, 2026 · 18 min
Cannabis science struggles to keep pace with a changing market
Why cannabis’s health effects are so hard to study
As products, delivery methods, and patterns of use evolve, weak evidence can shape medical advice, consumer safety, and public policy.
- 1Teen cannabis use was associated with less cognitive improvement than peers in a longitudinal study of roughly 11,000 children.
- 2Cannabis may help with pain and chemotherapy-related symptoms, while low THC doses could offer benefits without intoxication.
- 3Legalization and commercial access have not eliminated the regulatory, logistical, and product-safety barriers facing researchers.
Don't miss
Natasha Wade explains findings from a longitudinal study of roughly 11,000 children, linking adolescent cannabis use with less cognitive improvement than peers.
The brief
Cannabis products and consumption methods are changing faster than the evidence base, leaving researchers to reassess questions about pain, sleep, long-term effects, and medical use.
Natasha Wade discusses adolescent development and a longitudinal study of roughly 11,000 children, in which cannabis-using teens showed less cognitive improvement than peers.
Ryan G. Vandrey explains where cannabinoids show promise, including pain and chemotherapy-related symptoms, and why very low THC doses may provide benefits without intoxication.
Legalization and commercial access have not solved research barriers; shifting regulations, product variation, and weak dispensary guidance still make safety claims difficult to evaluate.
The guests argue that honest, relative-risk conversations with teens matter because cannabis questions are nuanced, while policy decisions cannot wait for a perfect evidence base.
Featuring
Ryan G. Vandrey
Johns HopkinsListen to the full episode and explore every guest, topic, and moment on PodLume.